Literature DB >> 29708466

Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation.

Maria Teresa Giordana1, Paola Cavalla1, Antonio Uccelli2, Alice Laroni2, Fabio Bandini3, Marco Vercellino1, Gianluigi Mancardi2.   

Abstract

We present the neuropathological description of an autoptic case of fatal rebound of disease activity after fingolimod discontinuation in a multiple sclerosis patient. MRI prior to the fatal outcome showed several large tumefactive demyelinating lesions. These lesions were characterized by prominent astrocytic gliosis, with a remarkable preponderance of large hypertrophic reactive astrocytes showing intense expression of sphingosine-1-phosphate receptor 1. Prominent astrocytic gliosis was also diffusely observed in the normal-appearing white matter. Dysregulated sphingosine-1-phosphate signaling on astrocytes following fingolimod withdrawal might represent a possible contributing mechanism to disease rebound and might account for the unusual radiological and neuropathological features observed in the present case.

Entities:  

Keywords:  Fingolimod; demyelination; glia; histopathology; multiple sclerosis; post mortem

Mesh:

Substances:

Year:  2018        PMID: 29708466     DOI: 10.1177/1352458518763095

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  10 in total

1.  Extensive Multiple Sclerosis Reactivation after Switching from Fingolimod to Rituximab.

Authors:  Trygve Holmøy; Øivind Torkildsen; Svetozar Zarnovicky
Journal:  Case Rep Neurol Med       Date:  2018-07-19

2.  Recurrent Fulminant Tumefactive Demyelination With Marburg-Like Features and Atypical Presentation: Therapeutic Dilemmas and Review of Literature.

Authors:  Aigli G Vakrakou; Dimitrios Tzanetakos; Theodore Argyrakos; Georgios Koutsis; Maria-Eleptheria Evangelopoulos; Elisabeth Andreadou; Maria Anagnostouli; Marianthi Breza; John S Tzartos; Elias Gialafos; Antonios N Dimitrakopoulos; Georgios Velonakis; Panagiotis Toulas; Leonidas Stefanis; Constantinos Kilidireas
Journal:  Front Neurol       Date:  2020-06-30       Impact factor: 4.003

3.  Different MRI patterns in MS worsening after stopping fingolimod.

Authors:  Caterina Lapucci; Damiano Baroncini; Maria Cellerino; Giacomo Boffa; Ilaria Callegari; Matteo Pardini; Giovanni Novi; Maria Pia Sormani; Giovanni Luigi Mancardi; Angelo Ghezzi; Mauro Zaffaroni; Antonio Uccelli; Matilde Inglese; Luca Roccatagliata
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-04-16

Review 4.  Does Siponimod Exert Direct Effects in the Central Nervous System?

Authors:  Markus Kipp
Journal:  Cells       Date:  2020-07-24       Impact factor: 6.600

5.  Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.

Authors:  Silvia Delgado; Jeffrey Hernandez; Leticia Tornes; Kottil Rammohan
Journal:  BMC Neurol       Date:  2021-02-02       Impact factor: 2.474

Review 6.  Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data.

Authors:  Kerri A Schoedel; Carine Kolly; Anne Gardin; Srikanth Neelakantham; Kasra Shakeri-Nejad
Journal:  Psychopharmacology (Berl)       Date:  2021-11-13       Impact factor: 4.530

Review 7.  Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects.

Authors:  Stefanie Fischer; Undine Proschmann; Katja Akgün; Tjalf Ziemssen
Journal:  Cells       Date:  2021-11-15       Impact factor: 6.600

Review 8.  Immunopathology of Tumefactive Demyelinating Lesions-From Idiopathic to Drug-Related Cases.

Authors:  Aigli G Vakrakou; Maria-Evgenia Brinia; Ioanna Svolaki; Theodore Argyrakos; Leonidas Stefanis; Constantinos Kilidireas
Journal:  Front Neurol       Date:  2022-03-15       Impact factor: 4.003

9.  Disease reactivation in a patient with secondary progressive multiple sclerosis after switching treatment from fingolimod to siponimod.

Authors:  Kensuke Senzaki; Hirofumi Ochi; Masayuki Ochi; Yoko Okada; Shiroh Miura; Yasumasa Ohyagi
Journal:  eNeurologicalSci       Date:  2021-05-15

10.  Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases.

Authors:  Aigli G Vakrakou; Dimitrios Tzanetakos; Maria-Eleptheria Evangelopoulos; Theodore Argyrakos; John S Tzartos; Maria Anagnostouli; Elissavet Andreadou; Georgios Koutsis; Georgios Velonakis; Panagiotis Toulas; Elias Gialafos; Antonios Dimitrakopoulos; Erasmia Psimenou; Leonidas Stefanis; Constantinos Kilidireas
Journal:  Ther Adv Neurol Disord       Date:  2021-05-18       Impact factor: 6.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.